Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small molecule PD-L1 inhibitor, in healthy and chronic hepatitis B (CHB) subjects

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
May 7-10, 2025
Amsterdam the Netherlands


Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small molecule PD-L1 inhibitor, in healthy and chronic hepatitis B (CHB) subjects

	EASL 2025 May 7-10 Amsterdam Edward Gane1